Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in ...

ALS medication AMX0114 has been well tolerated in early clinical testing, and is now moving to a second, higher-dose trial ...

New grading scales for ocular adverse events in oncology improve clarity and provide drug-dose-modification recommendations, ...

Ianalumab, a monoclonal antibody, helped patients with immune thrombocytopenia (ITP) maintain safe platelet counts without ...

Citius Oncology entered into an exclusive distribution agreement with Er-Kim to expand international access to Lymphir (denileukin diftitox-cxdl) in Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly drug candidate retatrutide achieved up to 28.7% weight loss and reduced knee osteoarthritis pain in a phase 3 trial of 445 adults.

Discover how in silico tools can be used can be used with organ-on-a-chip for the advancement of ADME studies.

A next-generation obesity shot from Eli Lilly and Co. helped patients lose almost a quarter of their body weight, potentially ...

Eli Lilly’s experimental weight-loss drug retatrutide led to an average weight reduction of up to 28.7%—more than 71 ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Eli Lilly's experimental weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a phase three trial involving patients with obesity and knee osteoarthritis. The ...